Mouse Monoclonal BCR antibody. Suitable for Flow Cyt, WB and reacts with Human samples. Immunogen corresponding to Recombinant Fragment Protein within Human BCR aa 100-300.
Preservative: 0.05% Sodium azide
Constituents: PBS
Flow Cyt | WB | |
---|---|---|
Human | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/200.00000 - 1/400.00000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/500.00000 - 1/2000.00000 | Notes - |
Select an associated product type
Protein with a unique structure having two opposing regulatory activities toward small GTP-binding proteins. The C-terminus is a GTPase-activating protein (GAP) domain which stimulates GTP hydrolysis by RAC1, RAC2 and CDC42. Accelerates the intrinsic rate of GTP hydrolysis of RAC1 or CDC42, leading to down-regulation of the active GTP-bound form (PubMed:17116687, PubMed:1903516, PubMed:7479768). The central Dbl homology (DH) domain functions as guanine nucleotide exchange factor (GEF) that modulates the GTPases CDC42, RHOA and RAC1. Promotes the conversion of CDC42, RHOA and RAC1 from the GDP-bound to the GTP-bound form (PubMed:23940119, PubMed:7479768). The amino terminus contains an intrinsic kinase activity (PubMed:1657398). Functions as an important negative regulator of neuronal RAC1 activity (By similarity). Regulates macrophage functions such as CSF1-directed motility and phagocytosis through the modulation of RAC1 activity (PubMed:17116687). Plays a major role as a RHOA GEF in keratinocytes being involved in focal adhesion formation and keratinocyte differentiation (PubMed:23940119).
BCR1, D22S11, BCR, Breakpoint cluster region protein, Renal carcinoma antigen NY-REN-26
Mouse Monoclonal BCR antibody. Suitable for Flow Cyt, WB and reacts with Human samples. Immunogen corresponding to Recombinant Fragment Protein within Human BCR aa 100-300.
Preservative: 0.05% Sodium azide
Constituents: PBS
Purified from tissue culture supernatant.
Abcam is leading the way to address reproducibility in scientific research with our highly validated recombinant monoclonal and recombinant multiclonal antibodies. Search & select one of Abcam's thousands of recombinant alternatives to eliminate batch-variability and unnecessary animal use.
If you do not find a host species to meet your needs, our catalogue and custom Chimeric range provides scientists the specificity of Abcam's RabMAbs in the species backbone of your choice. Remember to also review our range of edited cell lines, proteins and biochemicals relevant to your target that may help you further your research goals.
Abcam antibodies are extensively validated in a wide range of species and applications, so please check the reagent specifications meet your scientific needs before purchasing. If you have any questions or bespoke requirements, simply visit the Contact Us page to send us an inquiry or contact our Support Team ahead of purchase.
The Bcr protein also known as breakpoint cluster region protein plays an important role in cellular signaling. It has a molecular mass of approximately 160 kDa and is expressed in many cell types such as hematopoietic cells. Bcr functions as a GTPase-activating protein (GAP) for p21rac and other small GTP-binding proteins. This activity influences cellular processes such as growth and differentiation. Bcr is also known for its involvement in the formation of the Bcr-Abl fusion protein an important factor in certain leukemias.
The Bcr protein acts within cells to regulate signal transduction and cytoskeletal organization. It is part of the pre-B cell receptor (pre-BCR) signaling complex influencing B-cell development. Its GAP activity is important for the regulation of small GTPases impacting cell migration and adhesion. Alterations in Bcr function can affect cellular responses such as apoptosis making it a focus for research into targeted therapies for hematological conditions.
The Bcr protein is an important player in signaling pathways involving the Ras superfamily of small GTPases. It is notably involved in the Rho GTPase pathway tied to cytoskeletal dynamics and cell cycle progression. Bcr's interaction with these pathways puts it in relation to proteins like Rac and Cdc42 which are vital for various cellular processes. Disruption in Bcr-associated pathways can lead to aberrant cell growth and metastasis.
Bcr has a well-documented link to certain leukemias particularly chronic myeloid leukemia (CML). The Bcr-Abl fusion protein resulting from the translocation of chromosomes 9 and 22 is central to CML pathology. Additionally Bcr connects with other proteins such as Abl in this disease context. Further disruptions in Bcr signaling can relate to disorders involving immune system dysregulation demonstrating the protein's relevance in both oncology and immunology research.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-Bcr antibody [1E11G12] (ab233709) at 1/500 dilution
All lanes: Recombinant human Bcr (aa139-28) protein
Developed using the ECL technique.
Predicted band size: 143 kDa
All lanes: Western blot - Anti-Bcr antibody [1E11G12] (ab233709) at 1/500 dilution
Lane 1: Untransfected HEK-293 (human epithelial cell line from embryonic kidney) cell lysate
Lane 2: Human Bcr (aa139-280)-IgG-Fc-transfected HEK-293 cell lysate
Developed using the ECL technique.
Predicted band size: 143 kDa
Flow cytometric analysis of K562 (human chronic myelogenous leukemia cell line from bone marrow) cells labeling Bcr with ab233709 at 1/200 dilution (green) compared with a negative control (red).
All lanes: Western blot - Anti-Bcr antibody [1E11G12] (ab233709) at 1/500 dilution
Lane 1: Jurkat (human T cell leukemia cell line from peripheral blood) cell lysate
Lane 2: HeLa (human epithelial cell line from cervix adenocarcinoma) cell lysate
Lane 3: Ramos (human Burkitt's lymphoma cell line) cell lysate
Developed using the ECL technique.
Predicted band size: 143 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com